Towada Products · New Delhi, India · Last updated:
Lapatinib is an oral dual HER2 and EGFR tyrosine kinase inhibitor used for HER2-positive advanced or metastatic breast cancer. Towada Products exports it from New Delhi, India, supplying Etibo and Lapakast in the 250mg strength to licensed buyers in Southeast Asia, the CIS region, the Middle East and select markets in Europe and Africa. Pricing is on enquiry.
Lapatinib is an oral tyrosine kinase inhibitor that blocks both HER2 (ErbB2) and EGFR (ErbB1). Unlike antibodies such as trastuzumab, it acts inside the cell on the kinase part of the receptor.
It is approved for HER2-positive advanced or metastatic breast cancer: in combination with capecitabine for patients who have received prior therapy including trastuzumab, and in combination with letrozole for postmenopausal women with hormone-receptor-positive, HER2-positive metastatic disease for whom hormone therapy is indicated. In Europe it is also approved in combination with trastuzumab for hormone-receptor-negative metastatic disease. The originator brand is Tykerb (Tyverb in Europe).
Capecitabine, letrozole and trastuzumab are all in our catalog, so breast oncology centres can order the combination partners together with lapatinib. The tablets are kept at room temperature and ship without a cold chain. Liver function and heart function are monitored during treatment. State the strength, pack size and quantity when you enquire.
Lapatinib is a prescription medicine, and whether it is suitable for a patient is a decision for the treating doctor. This page describes the medicine for trade buyers; it is not medical advice.
Every lapatinib product page on this site. "Listed for" is the use given in our catalog. Availability is confirmed when you enquire.
| Product | Composition | Listed for |
|---|---|---|
| Etibo 250mg | Lapatinib (250mg) | Breast cancer |
| Lapakast 250mg | Lapatinib (250mg) | HER2-positive metastatic breast cancer |
Export markets we serve: Southeast Asia, the CIS region, the Middle East and select markets in Europe and Africa. See our export markets →
Tell us which documents your regulator or customs broker needs and we will confirm what applies to the product you are ordering.
Lapatinib is an oral dual HER2 and EGFR tyrosine kinase inhibitor used for HER2-positive advanced or metastatic breast cancer. It is a prescription medicine, and whether it is suitable for a patient is a decision for the treating doctor.
Our catalog has 2 lapatinib product pages in the 250mg strength, from 2 brands: Etibo and Lapakast. The table on this page links to each product page; availability is confirmed when you enquire.
We ship from New Delhi by international courier or air cargo to licensed buyers in Southeast Asia, the CIS region, the Middle East and select markets in Europe and Africa, and have country pages for the Philippines, Russia, Kazakhstan, Uzbekistan, Iraq, Saudi Arabia and Brazil. Whether lapatinib can be imported, and by whom, is decided by the destination country's medicines regulator, so tell us the country and we will confirm what is possible. Every country we cover is listed on our export markets page.
Each shipment travels with a commercial invoice, a packing list and a courier or air waybill. We provide a Certificate of Analysis (CoA) for the batch and, where it is available for the product and the destination country requires it, a Certificate of Pharmaceutical Product (CoPP). A certificate of origin can be arranged on request.
Use the enquiry form on this page, WhatsApp +91 99995 62955 or email H.S.Gandhi@towadaproducts.in. Tell us the brand, strength, quantity and destination country, and we will reply with availability and a formal quotation.
This page is general information for trade buyers. It is not medical advice. Import rules differ by country and change over time; confirm the current requirements with your national medicines regulator before ordering.
Tell us the brand, strength, quantity and destination country. Pricing is confirmed in a formal quote. Prefer WhatsApp? Message +91 99995 62955.
Plain answers to the questions importers ask before ordering medicines from India.
